Julia K Rotow
Overview
Explore the profile of Julia K Rotow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blakely C, Urisman A, Gubens M, Mulvey C, Allen G, Shiboski S, et al.
J Clin Oncol
. 2024 Jul;
42(26):3105-3114.
PMID: 39028931
Purpose: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA -mutated...
2.
Haderk F, Chou Y, Cech L, Fernandez-Mendez C, Yu J, Olivas V, et al.
Nat Commun
. 2024 May;
15(1):3741.
PMID: 38702301
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC)...
3.
Sharp J, Jones D, Rotow J, Fidias P, Bertino E, Owen D
J Natl Compr Canc Netw
. 2024 Mar;
22(3).
PMID: 38479107
Mutations in BRAF are present in 4% of non-small cell lung cancer (NSCLC), of which half are well-characterized activating variants affecting codon 600 (classified as class I). These mutations, most...
4.
Caswell D, Gui P, Mayekar M, Law E, Pich O, Bailey C, et al.
Nat Genet
. 2023 Dec;
56(1):60-73.
PMID: 38049664
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR...
5.
Makarem M, Rotow J
J Thorac Oncol
. 2023 Nov;
18(12):1615-1617.
PMID: 37993212
No abstract available.
6.
Rotow J, Lee J, Madison R, Oxnard G, Janne P, Schrock A
J Thorac Oncol
. 2023 Oct;
19(2):227-239.
PMID: 37806383
Introduction: The emergence of osimertinib as standard of care for EGFR-mutant NSCLC has renewed the need to understand and overcome drug resistance. We sought to understand the genomics and real-world...
7.
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
Banla L, Tzeng A, Baillieul J, Kandekhar M, Fitzgerald K, Lopiccolo J, et al.
JTO Clin Res Rep
. 2023 Sep;
4(10):100559.
PMID: 37732171
Introduction: Thoracic radiotherapy (TRT) is increasingly used in patients receiving osimertinib for advanced NSCLC, and the risk of pneumonitis is not established. We investigated the risk of pneumonitis and potential...
8.
Ji J, Aredo J, Piper-Vallillo A, Huppert L, Rotow J, Husain H, et al.
JTO Clin Res Rep
. 2023 Mar;
4(3):100459.
PMID: 36879929
Introduction: mutations drive a subset of NSCLC. Patients harboring the common mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. Nevertheless, the effect...
9.
Piper-Vallillo A, Rotow J, Aredo J, Shaverdashvili K, Luo J, Carlisle J, et al.
JTO Clin Res Rep
. 2022 May;
3(6):100328.
PMID: 35637759
Introduction: This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib 80 mg in -mutant NSCLC. Methods: Retrospective review...
10.
Lee Y, Clark E, Milan M, Champagne C, Michael K, Awad M, et al.
JCO Precis Oncol
. 2020 Oct;
4.
PMID: 33015530
Purpose: Genomic analysis of plasma cell-free DNA has become a widespread tool for advanced non-small-cell lung cancer care. Whereas accuracy has been reported on widely, its usefulness is also tied...